Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1285, 2001-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel plus cisplatin increases survival, costs in ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Paclitaxel plus cisplatin increases survival, costs in ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 370, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

By Chen Kai   Chen Wan   Chen Xia   Jia Yi   Peng Gui   Chen Li  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium

By Neymark N.  

PharmacoEconomics, Vol. 20, Iss. 7, 2002-01 ,pp. : 485-497

Adis International

Access to resources Recommend Favorite

Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite